Professor Sarfaraz Niazi Convinces the US Senate to Vote on Removing Interchangeable Status of Biosimilars wsiltv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wsiltv.com Daily Mail and Mail on Sunday newspapers.
After reflecting upon the events of the past twelve months, Patent Docs presents its 15th annual list of top patent stories. For 2021, we identified nine stories that were covered on.
On October 15th, the Food and Drug Administration approved its second interchangeable biosimilar drug. That drug is Cyltezo (adalimumab-adbm), produced by Boehringer Ingelheim, which.